Taysha Gene Therapies (TSHA) Other Non-Current Liabilities (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Other Non-Current Liabilities data on file, last reported at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 31.83% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (up 31.83% YoY), and the FY2025 full-year result was $1.6 million, up 18.56% from the prior year.
• Other Non-Current Liabilities grew to $1.6 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.1 million in Q4 2022 to a low of $1.2 million in Q1 2025.
• A 5-year average of $2.4 million and a median of $1.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities surged 354.9% in 2022 and tumbled 64.81% in 2024, its largest moves.
• Tracing TSHA's Other Non-Current Liabilities over 5 years: stood at $4.1 million in 2022, then slumped by 61.82% to $1.6 million in 2023, then declined by 16.99% to $1.3 million in 2024, then rose by 18.56% to $1.6 million in 2025, then increased by 1.93% to $1.6 million in 2026.
• Business Quant data shows TSHA's Other Non-Current Liabilities at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.